What ASCVD risk percentage indicates that statin therapy should be considered?

What ASCVD risk percentage indicates that statin therapy should be considered?

• A. 5%
• B. 10%
• C. 7.5%
• D. 15%

Answer: (C)

The guideline outlines that atherosclerotic cardiovascular disease (ASCVD) risk assessment is crucial for determining whether a patient should be initiated on statin therapy. According to the recommendations provided by various health authorities, particularly the American College of Cardiology and American Heart Association, a 10-year ASCVD risk of 7.5% or greater is the threshold at which statin therapy should be considered for primary prevention in certain populations. Patients with a 10-year ASCVD risk of this level are typically those who might benefit most from the cholesterol-lowering effects of statins, especially when other risk factors such as hypertension, diabetes, or smoking are present. The recommendation aims to target those at significant risk for cardiovascular events, allowing for preventive measures to lower their overall incidence of heart attack and stroke. A risk percentage of 7.5% indicates a moderate level of risk, where the potential benefits of statin therapy outweigh the risks, leading to better long-term outcomes. Therefore, initiating statin therapy at or above this risk level is supported by evidence showing reductions in cardiovascular events. While values like 5%, 10%, or 15% may also be considered in clinical discussions about cardiovascular risk, the specific recommendation for initiating statin therapy is firmly

The guideline outlines that atherosclerotic cardiovascular disease (ASCVD) risk assessment is crucial for determining whether a patient should be initiated on statin therapy. According to the recommendations provided by various health authorities, particularly the American College of Cardiology and American Heart Association, a 10-year ASCVD risk of 7.5% or greater is the threshold at which statin therapy should be considered for primary prevention in certain populations.

Patients with a 10-year ASCVD risk of this level are typically those who might benefit most from the cholesterol-lowering effects of statins, especially when other risk factors such as hypertension, diabetes, or smoking are present. The recommendation aims to target those at significant risk for cardiovascular events, allowing for preventive measures to lower their overall incidence of heart attack and stroke.

A risk percentage of 7.5% indicates a moderate level of risk, where the potential benefits of statin therapy outweigh the risks, leading to better long-term outcomes. Therefore, initiating statin therapy at or above this risk level is supported by evidence showing reductions in cardiovascular events.

While values like 5%, 10%, or 15% may also be considered in clinical discussions about cardiovascular risk, the specific recommendation for initiating statin therapy is firmly